HRES 95
114th Congress
House
Health
Advanced technology and technological innovations
Biological and life sciences
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Executive agency funding and structure
Food and Drug Administration (FDA)
Health programs administration and funding
Health technology, devices, supplies
Medical research
Research administration and funding
Research and development
Recognizing the importance of transformative breakthroughs in biomedicine, biotechnology, and life sciences in the diagnosis, management, curing, and treatment of illness and the existence of a "Valley of Death" in biotechnology and life sciences funding that stifles innovation and impedes translational medical research.
Introduced: February 5, 2015
Introduced by:
Vargas, Juan
Democratic
· California
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 6, 2015
Referred to the Subcommittee on Health.
Feb 5, 2015
Referred to the House Committee on Energy and Commerce.
Feb 5, 2015
Introduced in House
Plain-English summary
Recognizes: the value of biomedicine, biotechnology, and life sciences; the challenges those industries face; and the ways those challenges can be addressed.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2
Cosponsors
1